Best-Selling Drugs Of 2019 Ten blockbuster medicines booked combined sales of $92.5bn in 2019. We examine the drugs that command the greatest revenues globally. Which therapeutic areas include the most lucrative blockbusters, which companies enjoy the spoils, and which drugs are new to the top 10? And what is the position of these products on the all-important US market?

TOP 10TOP 10 LEAGUE TABLE

Rituxan(rituximab)

Avastin(bevacizumab)

Enbrel(etanercept)

Eylea(aflibercept)

Eliquis(apixaban)

Opdivo(nivolumab)

Imbruvica(ibrutinib)

Revlimid(lenalidomide)

Keytruda(pembrolizumab)

Humira(adalimumab)

RANK

1

2

3

4

5

6

7

8

9

10

% CHANGE

-3.8

+54.6

-3.2

+30.3

+4.7

+23.2

+11.8

-3.6

+0.7

-6.4

19.620.4

11.17.2

9.49.7

8.16.2

8.07.6

7.96.4

7.56.7

7.27.5

7.17.1

6.57.0

KEY 2019 Sales 2018 Sales

2019

vs

2018

+7%CHANGEIN TOTAL SALES

$92.5bn$85.8bn

TO 11TH PLACEfrom 10th

TO 13TH PLACEfrom 5th

JOINING THE TOP 10

TO 6TH PLACEfrom 11th

TO 4TH PLACEfrom 12th

DEPARTING THE TOP 10

BIOLOGICS DOMINATE, IN CANCER AND AUTOIMMUNE DISORDERS

2018Sales

18%

2019Sales

27%

73%$67.0bn

82%$70.7bn

Small Molecules BiologicsKEY

4Autoimmune/Immunology

¢ Humira¢ Imbruvica¢ Enbrel¢ Rituxan

1Cardiovascular

¢ Eliquis

2Ophthalmology

¢ Eylea¢ Humira

6Oncology

¢ Keytruda¢ Revlimid¢ Imbruvica¢ Opdivo¢ Avastin¢ Rituxan

THERAPY AREAS

AbbVie$33.3bn

Humira 58%Imbruvica 14%

Ono PharmaceuticalJPY227bn

Opdivo 39%

Merck & Co$46.8bn

Keytruda 24%

Amgen$23.4bn

Enbrel 22%

RocheCHF61.5bn

Avastin 12%Rituxan 11%

Pfizer$51.8bn

Enbrel 3%Eliquis 8%

RegeneronPharmaceuticals

$7.9bn

Eylea 59%

Bristol-Myers Squibb$26.1bn

Eliquis 30%Opdivo 28%

Revlimid* 5%

Company Name, Total RevenuesKEY

Percentage figure = product's contribution to total revenues*from 20 November 2019 following acquisition of Celgene

WHICH COMPANIES RELY MOST HEAVILY ON TOP 10 DRUGS?

Only brand with a majority

of ex-US sales

SALES AND PRICE RISES IN US

*AWP unit list price in red book; AWP = average wholesale price; figures calculated based on prices listed for most of each year

$59.2bnTotal US Sales

62%Average proportion

of sales represented by USfor top 10 drugs in 2019

RituxanAvastinEnbrelEyleaEliquisOpdivoImbruvicaRevlimidKeytrudaHumira

24%$4,756m

43%$4,779m

33%$3,081m

33%$2,700m

46%$3,662m

40%$3,174m

38%$2,896m

30%$2,163m

57%$4,080m

31%$2,002m

69%$4,517m

+0.0%

43%$3,038m

+0.0%

70%$5,050m

+6.2%

62%$4,644m

+0.0%

60%$4,755m

+6.0%

54%$4,344m

+3.0%

67%$5,385m

+6.2%

67%$6,297m

+3.5%

57%$6,305m

+1.5%

76%$14,864m

+7.4% KEY US Rest of world% AWP increase from 2018 to 2019 indicated at top of each bar

Humira

Keytruda

Revlimid

Imbruvica

Opdivo

Eliquis

Eylea

Enbrel

Avastin

Rituxan

2000 2005 2010 2015 2020 2025

US MARKET EXCLUSIVITY TIMELINE

201

9Only two faced US biosimilar/generic competition in 2019

*expected loss of US exclusivity according to Datamonitor Healthcare

202520242023202220212020

Revlimid

Total

CAGR

$46.3bn $49.0bn $49.5bn $47.2bn $45.0bn $43.2bn

Humira

Keytruda

4.1%

-7.7%

6.8%

GLOBAL SALES OUTLOOK: TOP THREEKeytruda ispoised to overtake Humira in 2023

Source: Pharmavitae/Datamonitor Healthcare

General sources: Datamonitor Healthcare, Company Annual Reports

ID: 950184